** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O rise 28.1% to $4.17 premarket
** Co says its experimental treatment to prevent surgical site infection in patients undergoing abdominal colorectal surgery met main goal of late-stage trial
** Treatment called D-PLEX100 is administered along with standard of care treatment to provide prolonged anti-bacterial activity directly at surgical site to prevent infections
** Co says treatment showed 58% reduction in rate of surgical site infections in patients treated with D-PLEX100 vs standard of care
** Co expects to submit marketing application to U.S. FDA in early 2026
** Up to last close, stock up 7.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.